Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase Ia Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of XQ-001 for Inhalation in Healthy Subjects

NCT06918366 is registered in ClinicalTrials.gov with Brilliant Inspiration Biotherapeutics as lead sponsor.

NCT NCT06918366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06918366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase Ia Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of XQ-001 for Inhalation in Healthy Subjects
Lead sponsor
Brilliant Inspiration Biotherapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 1, 2024
Completion date
May 30, 2025
Enrollment
58 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy